Organon & Co.
OGN NYSE· Pharmaceutical Preparations
Last close · Oct 26, 2026
$13.74
KIRA · Stoqly’s AI analyst, in plain words
- Organon & Co. had $6.2B of revenue in fiscal 2025, down 2.9% on the year before. Over five years, revenue changed −1.0% a year on average.
- Organon & Co. made $187M of net profit in fiscal 2025. From fiscal 2019 to 2025, diluted EPS grew −38.0% a year.
- Free cash flow was $538M in fiscal 2025, 8.7% of revenue.
- Organon & Co. returned $88.0M to shareholders in fiscal 2025, 16% of free cash flow. The diluted share count rose 0.6%.
- Organon & Co. owes $8.1B more than it holds in cash.
Market cap
$3.7B
P/E
17.6x
Revenue
$6.2B
Net income
$187M
Free cash flow
$538M
Operating margin
—
Organon & Co. in 30 seconds · fiscal 2025
Are sales growing?
−2.9%
No. Sales fell 2.9% last year.
Does it make a profit?
3.0%
A little. It keeps 3.0% of every sale as profit.
Does profit turn into cash?
8.7%
Partly. 8.7% of sales ends up as free cash.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
17.6x
One share costs 17.6 times its yearly profit per share.
What Organon & Co. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 24, 2026
- Legal name
- Organon & Co.
- CIK
- 0001821825
Organon & Co. · OGN
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $6.3B | $6.2B | $6.3B | $6.4B | $6.2B |
| Revenue growth | −3.5% | −2.1% | 1.4% | 2.2% | −2.9% |
| Gross margin | 62.2% | 62.8% | 59.8% | 58.0% | 53.3% |
| Net income | $1.4B | $917M | $1.0B | $864M | $187M |
| Net margin | 21.4% | 14.9% | 16.3% | 13.5% | 3.0% |
| Diluted EPS | $5.31 | $3.59 | $3.99 | $3.33 | $0.72 |
| Cash | |||||
| Cash from operations | $2.2B | $858M | $799M | $939M | $700M |
| Capital expenditure | $192M | $196M | $251M | $175M | $162M |
| Free cash flow | $2.0B | $662M | $548M | $764M | $538M |
| FCF margin | 31.2% | 10.7% | 8.7% | 11.9% | 8.7% |
| Dividends paid | $145M | $290M | $294M | $297M | $88.0M |
| Share count change | 0.3% | 0.4% | 0.4% | 1.1% | 0.6% |
| Debt and strength | |||||
| Cash and short-term investments | $737M | $706M | $693M | $675M | $574M |
| Debt incl. finance leases | $9.1B | $8.9B | $8.8B | $8.9B | $8.7B |
| Shareholders' equity | −$1.5B | −$892M | −$70.0M | $472M | $752M |
| Current ratio | 1.4x | 1.6x | 1.5x | 1.6x | 1.8x |
| Returns and quality | |||||
| Return on equity | 67.9% | — | — | 429.9% | 30.6% |
| Piotroski F-score | 4 | 5 | 4 | 5 | 5 |
Insiders bought, 12 months
$0.9M
2 insiders
Insiders sold, 12 months
$0.2M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Organon & Co. · OGN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $13.74 a share, the company is worth $3.7B: 17.6 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001821825). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.